AVXL Archives - BioTuesdays

Developments

Anavex reports positive results from Phase 2 Parkinson’s disease trial

Anavex Life Sciences (NASDAQ:AVXL) reported positive results from its Phase 2 study evaluating ANAVEX2-73 for the treatment of Parkinson’s disease dementia. The proof-of-concept study enrolled 132 patients who received...

October 15, 2020

Developments

Anavex gets fast track designation for Rett Syndrome drug candidate

The FDA granted fast track designation to Anavex Life Sciences’ (NASDAQ:AVXL) ANAVEX2-73 for the treatment of Rett syndrome. Rett syndrome is a genetic neurodevelopmental disorder characterized by severe physical and...

February 3, 2020

Developments

Anavex presents two-year data from Phase 2a AD trial

Anavex Life Sciences (NASDAQ:AVXL) presented interim two-year data from its Phase 2a extension study of ANAVEX2-73 in Alzheimer’s disease (AD) patients at the 2019 clinical trials on AD conference. ANAVEX2-73 is...

December 5, 2019

Developments

Dawson James starts Anavex at buy: PT $16

Dawson James initiated coverage of Anavex Life Sciences (NASDAQ:AVXL) with a “buy” rating and $16 price target. The stock closed $2.54 on July 23. Anavex is pioneering a new treatment in CNS diseases like...

July 24, 2019

Developments

Anavex reports gut microbiota linked to improved ANAVEX2-73 response

Anavex Life Sciences (NASDAQ:AVXL) reported that Alzheimer’s disease (AD) patients with high levels of two gut microbiota families had an improved response to ANAVEX2-73. ANAVEX2-73 is an orally-administered liquid...

July 19, 2019

Markets

Roth starts coverage of 3 companies with novel approaches to AD

Roth Capital Partners initiated coverage of three companies – vtv Therapeutics (NASDAQ:VTVT), Anevex Life Sciences (NASDAQ:AVXL) and Neurotrope Biosciences (NASDAQ:NTRP) – that are developing drugs with novel...

March 9, 2018

Feature

Anavex readies trial of AZ combo drug

By Len Zehr Anavex Life Sciences (OTCQB:AVXL) plans to begin a Phase 1b/2a clinical trial in the first quarter of 2014 of a novel combination drug candidate for the treatment of Alzheimer’s disease (AD). “In preclinical...

December 17, 2013

Tag - AVXL

Anavex reports positive results from Phase 2 Parkinson’s disease trial

Anavex gets fast track designation for Rett Syndrome drug candidate

Anavex presents two-year data from Phase 2a AD trial

Dawson James starts Anavex at buy: PT $16

Anavex reports gut microbiota linked to improved ANAVEX2-73 response

Roth starts coverage of 3 companies with novel approaches to AD

Anavex readies trial of AZ combo drug

General

More